Search results
Results from the WOW.Com Content Network
The national drug code (NDC) is a unique product identifier used in the United States for drugs intended for human use. The Drug Listing Act of 1972 [ 1 ] [ 2 ] requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed ...
The U.S. Food and Drug Administration (FDA) in the 2006 Compliance Policy Guide for the Prescription Drug Marketing Act states that: "A drug pedigree is a statement of origin that identifies each prior sale, purchase, or trade of a drug, including the date of those transactions and the names and addresses of all parties to them."
National Drug Code (NDC) — administered by Food and Drug Administration. [1] Drug Identification Number (DIN) — administered by Health Canada under the Food and Drugs Act; Hong Kong Drug Registration — administered by the Pharmaceutical Service of the Department of Health (Hong Kong) National Pharmaceutical Product Index - South Africa
DailyMed is a website operated by the U.S. National Library of Medicine (NLM) to publish up-to-date and accurate drug labels (also called a "package insert") to health care providers and the general public. The contents of DailyMed is provided and updated daily by the U.S. Food and Drug Administration (FDA). The FDA in turn collects this ...
The Generic Product Identifier (GPI) is a 14-character hierarchical classification system created by Wolters Kluwer's Medi-Span that identifies drugs from their primary therapeutic use down to the unique interchangeable product regardless of manufacturer or package size. The code consists of seven subsets, each providing increasingly more ...
The National Council for Prescription Drug Programs (NCPDP) is an American nonprofit standards development organization representing most sectors of the U.S. pharmacy services industry. It was founded in 1977 as the extension of a Drug Ad Hoc Committee that made recommendations for the U.S. National Drug Code (NDC).
The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines (usually to clinical investigators) before a marketing application for the drug has been approved.
Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis, but this trial was completed in October 2009. [12] Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease , [ 13 ] gout , and coronary artery disease (the CANTOS trial [ 14 ] ).